Current Neurology and Neuroscience Reports

, Volume 7, Issue 6, pp 513–521 | Cite as

Osmotherapy in neurocritical care

Article

Abstract

Osmotherapy is the mainstay in the medical management of cerebral edema with or without elevations in intracranial pressure. Several osmotic agents have been utilized in clinical practice over the past five decades in a variety of brain injury paradigms. The over-riding premise for their beneficial effects has been via egress of water from the brain into the vascular compartment. In addition, many of these agents have beneficial extraosmotic properties that portend their use in cerebral resuscitation and treatment of cerebral edema. Although there is a paucity of large, randomized clinical trials that compare various osmotic agents, data are emerging from prospective clinical case series. This article provides a historical perspective of osmotherapy, examines characteristics of osmotic agents, and discusses caveats in their use in the clinical setting. Furthermore, this review highlights the utility of osmotic agents as tools to understand emerging mechanistic concepts in the evolution of brain edema, which are yielding important data of translational significance from laboratory-based research.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Paczynski RP: Osmotherapy: basic concepts and controversies. Crit Care Clin 1997, 13:105–129.PubMedCrossRefGoogle Scholar
  2. 2.
    Bhardwaj A, Ulatowski JA: Cerebral edema: hypertonic saline solutions. Curr Treat Options Neurol 1999, 1:179–188.PubMedCrossRefGoogle Scholar
  3. 3.
    Qureshi AI, Suarez JI: Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension. Crit Care Med 2000, 28:3301–3313.PubMedCrossRefGoogle Scholar
  4. 4.
    Harukuni I, Kirsch JR, Bhardwaj A: Cerebral resuscitation: role of osmotherapy. J Anesth 2002, 16:229–237.PubMedCrossRefGoogle Scholar
  5. 5.
    Bhardwaj A, Ulatowski JA: Hypertonic saline solutions in brain injury. Curr Opin Crit Care 2004, 10:126–131.PubMedCrossRefGoogle Scholar
  6. 6.
    Ogden AT, Mayer SA, Connolly ES: Hypersomolar agents in neurosurgical practice: the evolving role of hypertonic saline. Neurosurgery 2005, 57:207–215.PubMedCrossRefGoogle Scholar
  7. 7.
    Raslan A, Bhardwaj A: Medical management of cerebral edema. Neurosurg Focus 2007, 22:E12.PubMedCrossRefGoogle Scholar
  8. 8.
    Ziai WC, Toung TJ, Bhardwaj A: Hypertonic saline: first-line therapy or cerebral edema? J Neurol Sci 2007, 261:157–166.PubMedCrossRefGoogle Scholar
  9. 9.
    Klatzo I: Neuropathological aspects of cerebral edema. J Neuropathol Exp Neurol 1967, 26:1–14.PubMedGoogle Scholar
  10. 10.
    Weed LH, McKibben PS: Experimental alteration of brain bulk. Am J Physiol 1919, 531–555.Google Scholar
  11. 11.
    Fermont-Smith F, Forbes HS: Intraocular and intracranial pressure: an experimental study. Arch Neurol Psychiatry 1927, 18:550–564.Google Scholar
  12. 12.
    Hughes J, Mudd S, Strecker EA: Reduction of elevated intracranial pressure by concentrated solutions of human lyophile serum. Arch Neurol Psych 1938, 12:1277–1287.Google Scholar
  13. 13.
    Javid M, Settlage P: Effect of urea on cerebrospinal fluid pressure in human subjects. JAMA 1956, 160:943–949.Google Scholar
  14. 14.
    Wise BL, Carter N: The value of hypertonic mannitol solution in decreasing brain mass and lowering cerebrospinal fluid pressure. J Neurosurg 1962, 19:1038–1043.PubMedCrossRefGoogle Scholar
  15. 15.
    Zornow MH: Hypertonic saline as a safe and efficacious treatment of intracranial hypertension. J Neurosurg Anesth 1996, 8:175–177.CrossRefGoogle Scholar
  16. 16.
    Schell RM, Applegate RL II, Cole DJ: Salt, starch, and water on the brain. J Neurosurg Anesth 1996, 8:178–182.Google Scholar
  17. 17.
    Agre P, King LS, Yasui M, et al.: Aquaporin water channels-from atomic structure to clinical medicine. J Physiol 2002, 542:3–16.PubMedCrossRefGoogle Scholar
  18. 18.
    Diringer MN, Zazulia AR: Osmotic therapy: fact and fiction. Neurocrit Care 2004, 1:219–233.PubMedCrossRefGoogle Scholar
  19. 19.
    Gondim FA, Aiyagari V, Shackleford A, Diringer MN: Osmolality not predictive of mannitol-induced acute renal insufficiency. J Neurosurg 2005, 103:444–447.Google Scholar
  20. 20.
    Toung TJ, Chen CH, Lin C, Bhardwaj A: Osmotherapy with hypertonic saline attenuates water content in brain and extracerebral organs. Crit Care Med 2007, 35:526–531.PubMedCrossRefGoogle Scholar
  21. 21.
    Cascino T, Baglivo J, Conti J, et al.: Quantitative CT assessment of furosemide-and mannitol-induced changes in brain water content. Neurology 1983, 33:898–903.PubMedGoogle Scholar
  22. 22.
    Cantore G, Guidetti B, Virno M: Oral glycerol for the reduction of intracranial pressure. J Neurosurg 1964, 21:278–283.PubMedGoogle Scholar
  23. 23.
    Brain Trauma Foundation, American Association of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care: Use of mannitol: Brain Trauma Foundation, The American Association of Neurological Surgeons, The Joint Section on Neurotrauma and Critical Care. J Neurotrauma 2000, 17:521–525.Google Scholar
  24. 24.
    Miller JD, Leech P: Effects of mannitol and steroid therapy on intracranial volume-pressure relationships in patients. J Neurosurg 1975, 42:274–281.PubMedCrossRefGoogle Scholar
  25. 25.
    Cottrell JE, Robustelli A, Post K, et al.: Furosemide-and mannitol-induced changes in intracranial pressure and serum osmolality and electrolytes. Anesthesiology 1977, 47:28–30.PubMedCrossRefGoogle Scholar
  26. 26.
    James HE, Langfitt TW, Kumar VS, et al.: Treatment of intracranial hypertension. Analysis of 105 consecutive, continuous recordings of intracranial pressure. Acta Neurochirsurgica 1977, 36:189–200.CrossRefGoogle Scholar
  27. 27.
    Marshall LF, Smith RW, Rauscher LA, et al.: Mannitol dose requirements in brain-injured patients. J Neurosurg 1978, 48:169–172.PubMedCrossRefGoogle Scholar
  28. 28.
    Muizelaar JP, Lutz HA, Becker DP: Effect of mannitol on ICP and CBF and correlation with pressure autoregulation in severely head-injured patients. J Neurosurg 1984, 61:700–706.PubMedCrossRefGoogle Scholar
  29. 29.
    Mendelow AD, Teasedale GM, Russell T, et al.: Effect of mannitol on cerebral blood flow and cerebral perfusion pressure in human head injury. J Neurosurg 1985, 63:43–48.PubMedGoogle Scholar
  30. 30.
    Smith HP, Kelly DL, McWhorter JM, et al.: Comparison of mannitol regimens in patients with severe head injury undergoing intracranial monitoring. J Neurosurg 1986, 65:820–824.PubMedGoogle Scholar
  31. 31.
    Fisher B, Thomas D, Peterson B: Hypertonic saline lowers raised intracranial pressure in children after head trauma. J Neurosurg Anesthesiol 1992, 4:4–10.PubMedCrossRefGoogle Scholar
  32. 32.
    Yu YL, Kumana CR, Lauder IJ, et al.: Treatment of acute cerebral hemorrhage with intravenous glycerol. A doubleblind, placebo-controlled, randomized trial. Stroke 1992, 23:967–971.PubMedGoogle Scholar
  33. 33.
    Gemma M, Cozzi S, Tommasino C, et al.: 7.5% hypertonic saline versus 20% mannitol during elective neurosurgical supratentorial procedures. J Neurosurg Anesth 1997, 9:329–334.CrossRefGoogle Scholar
  34. 34.
    Qureshi AI, Suarez JI, Bhardwaj A, et al.: Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: effect on intracranial pressure and lateral displacement of the brain. Crit Care Med 1998, 26:440–446.PubMedCrossRefGoogle Scholar
  35. 35.
    Suarez JI, Qureshi AI, Bhardwaj A, et al.: Treatment of refractory intracranial hypertension with 23.4% saline. Crit Care Med 1998, 26:1118–1122.PubMedCrossRefGoogle Scholar
  36. 36.
    Shackford SR, Bourguignon PR, Wald SL, et al.: Hypertonic saline resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma 1998, 44:50–58.PubMedGoogle Scholar
  37. 37.
    Simma B, Burger R, Falk M, et al.: A prospective, randomized, and controlled study of fluid management in children with severe head injury: lactated Ringer’s solution versus hypertonic saline. Crit Care Med 1998, 26:1265–1270.PubMedCrossRefGoogle Scholar
  38. 38.
    Schwarz S, Schwab S, Bertram M, et al.: Effect of hypertonic saline hydroxyethyl starch solution and mannitol in patients with increased intracranial pressure after stroke. Stroke 1998, 29:1550–1555.PubMedGoogle Scholar
  39. 39.
    Horn P, Munch E, Vajkoczy P, et al.: Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates. Neurol Res 1999, 21:758–764.PubMedGoogle Scholar
  40. 40.
    Bereczki D, Mihalka L, Szatmari S, et al.: Mannitol use in acute stroke: case fatality at 30 days and 1 year. Stroke 2003, 34:1730–1735.PubMedCrossRefGoogle Scholar
  41. 41.
    Bensten G, Breivik H, Lundar T, Stubhaug A: Predictable reduction of intracranial hypertension with hypertonic saline hydroxyethyl starch: a prospective clinical trial in critically ill patients with subarachnoid hemorrhage. Acta Anaesthesiol Scand 2004, 48:1089–1095.CrossRefGoogle Scholar
  42. 42.
    Ware ML, Nemani VM, Meeker M, et al.: Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: a preliminary study. Neurosurgery 2005, 7:727–736.CrossRefGoogle Scholar
  43. 43.
    Wakai A, Roberts I, Schierhout G: Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev 2007, (1):CD001049.Google Scholar
  44. 44.
    Kalita J, Misra UK, Ranjan P, et al.: Effect of mannitol on regional cerebral blood flow in patients with intracerebral hemorrhage. J Neurol Sci 2004, 224:19–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Misra UK, Kalita J, Ranjan P, Mandal SK: Mannitol in intracerebral hemorrhage: a randomized controlled study. J Neurol Sci 2005, 234:41–45.PubMedCrossRefGoogle Scholar
  46. 46.
    Schwarz S, Georgiadis D, Aschoff A, Schwab S: Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. Stroke 2002, 33:136–140.PubMedCrossRefGoogle Scholar
  47. 47.
    Suarez JI, Qureshi AI, Parekh PD, et al.: Administration of hypertonic (3%) sodium chloride/acetate in hyponatremic patients with symptomatic vasospasm following subarachnoid hemorrhage. J Neurosurg Anesthesiol 1999, 11:178–184.PubMedCrossRefGoogle Scholar
  48. 48.
    Tseng MY, Al-Rawi PG, Pickard JD, et al.: Effect of hypertonic saline on cerebral blood flow in poor-grade patients with subarachnoid hemorrhage. Stroke 2003, 34:1389–1396.PubMedCrossRefGoogle Scholar
  49. 49.
    Karnat P, Vats A, Gross M, et al.: Use of hypertonic saline for the treatment of altered mental status associated with diabetic ketoacidosis. Pediatr Crit Care Med 2003, 4:239–242.CrossRefGoogle Scholar
  50. 50.
    Murphy N, Auzinger G, Bernel W, Wendon J: The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004, 39:464–470.PubMedCrossRefGoogle Scholar
  51. 51.
    Qureshi AI, Wilson DA, Traystman RJ. Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage: comparison between mannitol and hypertonic saline. Neurosurgery 1999, 44:1055–1063.PubMedCrossRefGoogle Scholar
  52. 52.
    Toung TJ, Tyler B, Brem H, et al.: Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor. J Neurosurg Anesthesiol 2002, 14:187–193.PubMedCrossRefGoogle Scholar
  53. 53.
    Manley GT, Fujimura M, Ma T, et al.: Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000, 6:159–163.PubMedCrossRefGoogle Scholar
  54. 54.
    Amiry-Moghaddam M, Otsuka T, Hurn PD, et al.: An alpha-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc Natl Acad Sci U S A 2003, 100:2106–2111.PubMedCrossRefGoogle Scholar
  55. 55.
    Chang Y, Chen TY, Chen CH, et al.: Plasma argininevasopressin following experimental stroke: effect of osmotherapy. J Appl Physiol 2006, 100:1445–1451.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Department of NeurologyOregon Health & Science UniversityPortlandUSA

Personalised recommendations